Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
60
MIRM Quote, Financials, Valuation and Earnings
Last price:
$71.57
Seasonality move
:
25.4%
Day range:
$69.86 - $71.98
52-week range:
$36.88 - $78.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.66x
P/B ratio:
12.49x
Volume:
643.1K
Avg. volume:
546.5K
1-year change:
57.31%
Market cap:
$3.6B
Revenue:
$336.9M
EPS (TTM):
-$0.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$130.5M | -$0.16 | 36.52% | -85.85% | $87.99 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 64.56% | -3.9% | $220.41 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
|
STOK
Stoke Therapeutics, Inc.
|
$6.2M | -$0.57 | -77.5% | -289.69% | $31.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$70.99 | $87.99 | $3.6B | -- | $0.00 | 0% | 7.66x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$31.16 | $31.63 | $3.8B | -- | $0.00 | 0% | 12.52x |
|
INSM
Insmed, Inc.
|
$206.78 | $220.41 | $44.1B | -- | $0.00 | 0% | 88.00x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.06 | $0.85 | $133.6M | 1.78x | $0.80 | 0% | 2.06x |
|
PFE
Pfizer Inc.
|
$25.57 | $29.04 | $145.4B | 14.90x | $0.43 | 6.73% | 2.32x |
|
STOK
Stoke Therapeutics, Inc.
|
$30.96 | $31.63 | $1.8B | 46.92x | $0.00 | 0% | 8.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
52.19% | 1.763 | 8.47% | 3.01x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
STOK
Stoke Therapeutics, Inc.
|
1.53% | 2.663 | 0.37% | 6.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$107.4M | $2.6M | -7.32% | -16.73% | 1.96% | $39.5M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
STOK
Stoke Therapeutics, Inc.
|
$9.6M | -$43.1M | 13.73% | 13.95% | -405.3% | -$30.5M |
Mirum Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns MIRM or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of 7.47%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About MIRM or ARQT?
Mirum Pharmaceuticals, Inc. has a consensus price target of $87.99, signalling upside risk potential of 23.95%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 1.49%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is MIRM or ARQT More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.
-
Which is a Better Dividend Stock MIRM or ARQT?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or ARQT?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 7.66x versus 12.52x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.7.66x -- $133M $2.9M ARQTArcutis Biotherapeutics, Inc.12.52x -- $99.2M $7.4M
-
Which has Higher Returns MIRM or INSM?
Insmed, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of -259.95%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About MIRM or INSM?
Mirum Pharmaceuticals, Inc. has a consensus price target of $87.99, signalling upside risk potential of 23.95%. On the other hand Insmed, Inc. has an analysts' consensus of $220.41 which suggests that it could grow by 6.59%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 INSMInsmed, Inc.16 1 0 -
Is MIRM or INSM More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock MIRM or INSM?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or INSM?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is higher than Insmed, Inc.'s net income of -$370M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 7.66x versus 88.00x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.7.66x -- $133M $2.9M INSMInsmed, Inc.88.00x -- $142.3M -$370M
-
Which has Higher Returns MIRM or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of -255.85%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About MIRM or NBY?
Mirum Pharmaceuticals, Inc. has a consensus price target of $87.99, signalling upside risk potential of 23.95%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is MIRM or NBY More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock MIRM or NBY?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or NBY?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 7.66x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.7.66x -- $133M $2.9M NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M
-
Which has Higher Returns MIRM or PFE?
Pfizer Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of 21.32%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About MIRM or PFE?
Mirum Pharmaceuticals, Inc. has a consensus price target of $87.99, signalling upside risk potential of 23.95%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 PFEPfizer Inc.7 15 1 -
Is MIRM or PFE More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock MIRM or PFE?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or PFE?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 7.66x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.7.66x -- $133M $2.9M PFEPfizer Inc.2.32x 14.90x $16.7B $3.6B
-
Which has Higher Returns MIRM or STOK?
Stoke Therapeutics, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of -360.68%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.
Company Gross Margin Earnings Per Share Invested Capital MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M STOKStoke Therapeutics, Inc.90.7% -$0.65 $312.9M -
What do Analysts Say About MIRM or STOK?
Mirum Pharmaceuticals, Inc. has a consensus price target of $87.99, signalling upside risk potential of 23.95%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 2.15%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Stoke Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MIRMMirum Pharmaceuticals, Inc.8 0 0 STOKStoke Therapeutics, Inc.9 0 0 -
Is MIRM or STOK More Risky?
Mirum Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.855% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.807%.
-
Which is a Better Dividend Stock MIRM or STOK?
Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIRM or STOK?
Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 46.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 7.66x versus 8.78x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MIRMMirum Pharmaceuticals, Inc.7.66x -- $133M $2.9M STOKStoke Therapeutics, Inc.8.78x 46.92x $10.6M -$38.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
